Stem Cell as Vehicles of Antibody in Treatment of Lymphoma: a Novel and Potential Targeted Therapy

Zhang, Jiayi; Zhang, Yuan; Zhong, Weide; Wei, Yaming

doi:10.1007/s12015-020-10080-z

Cited by 5 publications

(6 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with the proliferation assay and Annexin V results, it was well identified that the cell viability and proliferation were not impaired after modified. Previous evidence indicated that MSCs were easy to be genetically modified and stay stable [ 17 , 34 ]. UCMSCs-Tandab(IL-6/CD20) secreting level was continuously increasing with the culture days, reached the peak concentration of 6273 ± 487 pg/ml at day 7, and was detectable even at day 30, suggesting that the secretion of the Tandab protein was continuous and stable.…”

Section: Discussionmentioning

confidence: 99%

“…In preclinical studies, the most common inserted gene fragments are cytokines, pro-apoptotic proteins, oncolytic proteins and antibodies targeting tumor cells [ 38 , 39 , 42 ]. The previous clinical trial results showed that genetically modified MSCs were safe and effective for treating patients with lymphoma [ 17 ]. MSCs expressing EGFRvIII light- and heavy-chain fragments have been shown effective in the treatment of mouse glioblastoma [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

“…Third, MSC could differentiate into osteoblasts, adipocytes and chondroblasts in vitro. Compared with other MSCs, UCMSCs have been regarded as a superior source for its ease to harvest, low immunogenicity and innate homing ability [15][16][17]. Previous studies have proven that the expansion and differentiation abilities of MSCs derived from other sources decrease significantly with age, whereas UCMSCs possess prolonged culture period and high proliferation capacity [18].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Construction of tandem diabody (IL-6/CD20)-secreting human umbilical cord mesenchymal stem cells and its experimental treatment on diffuse large B cell lymphoma

Zhang

Zhong

et al. 2022

Stem Cell Res Ther

Self Cite

View full text Add to dashboard Cite

Background More than 40% patients with diffuse large B cell lymphoma (DLBCL) experienced relapse or refractory (R/R) lymphoma after the standard first R-CHOP therapy. IL-6 was reportedly associated with chemotherapy resistance of rituximab. Further, mesenchymal stem cells (MSCs) are known as the potential cell vehicle for their tropism toward tumor. A MSCs-based tandem diabody for treating DLBCL is currently lacking. Methods We constructed a tandem diabody (Tandab(IL-6/CD20)) with modified umbilical cord MSCs (UCMSCs) and designed a cell-based Tandab releasing system. Western blot, qPCR and immunofluorescence were used to confirm the construction and expression of lentivirus-infected UCMSCs. The vitality, apoptosis and homing abilities of UCMSCs were examined via CCK-8 assay, apoptosis, wound healing and migration analysis. Cell binding assay was used to demonstrate the targeting property of Tandab binding to CD20-positive DLBCL cells. Furthermore, we evaluated the viability of SU-DHL-2 and SU-DHL-4 by using CCK-8 and EDU assay after the treatment of UCMSCs-Tandab(IL-6/CD20). Results Tandab protein peaked at 6273 ± 487 pg/ml in the medium on day 7 after cell culture. The proliferation and homing ability of UCMSCs did not attenuate after genetically modification. Immunofluorescence images indicated the Tandab protein bound to the lymphoma cells. UCMSCs-Tandab(IL-6/CD20) inhibited the growth of SU-DHL-2 or SU-DHL-4 cells in vitro. Conclusions UCMSCs-Tandab(IL-6/CD20), which bound with both tumor-associated surface antigens and pro-tumor cytokines in tumor microenvironment, might serve as a potential treatment for DLBCL, evidenced by inhibiting the growth of SU-DHL-2 or SU-DHL-4 cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Construction of tandem diabody (IL-6/CD20)-secreting human umbilical cord mesenchymal stem cells and its experimental treatment on diffuse large B cell lymphoma

Zhang

Zhong

et al. 2022

Stem Cell Res Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, secreted factors of MSCs may reach the retina even while the inner restricted membrane prevents MSCs migration [75]. In this way, embryonic stem cell ESCs can also be used as vehicles for the delivery of agents to damaged tissue [76,77]. As an example, MSCs have been shown to efficiently and specifically carry drug-loaded polymeric nanoparticles by efflux transporters, such as overexpressed P-glycoprotein, since they are highly drug resistant [78].…”

Section: Stem Cells and Their Clinical Potential For Retinal Diseasesmentioning

confidence: 99%

Nanocarriers, Progenitor Cells, Combinational Approaches, and New Insights on the Retinal Therapy

Pishavar

Luo

Bolander

et al. 2021

IJMS

View full text Add to dashboard Cite

Progenitor cells derived from the retinal pigment epithelium (RPECs) have shown promise as therapeutic approaches to degenerative retinal disorders including diabetic retinopathy, age-related macular degeneration and Stargardt disease. However, the degeneration of Bruch’s membrane (BM), the natural substrate for the RPE, has been identified as one of the major limitations for utilizing RPECs. This degeneration leads to decreased support, survival and integration of the transplanted RPECs. It has been proposed that the generation of organized structures of nanofibers, in an attempt to mimic the natural retinal extracellular matrix (ECM) and its unique characteristics, could be utilized to overcome these limitations. Furthermore, nanoparticles could be incorporated to provide a platform for improved drug delivery and sustained release of molecules over several months to years. In addition, the incorporation of tissue-specific genes and stem cells into the nanostructures increased the stability and enhanced transfection efficiency of gene/drug to the posterior segment of the eye. This review discusses available drug delivery systems and combination therapies together with challenges associated with each approach. As the last step, we discuss the application of nanofibrous scaffolds for the implantation of RPE progenitor cells with the aim to enhance cell adhesion and support a functionally polarized RPE monolayer.

show abstract

“…It has been reported that lymphoma accounts for 3.2 % of all new cases of tumor around the world and most of the cases of NHL (87.5 %) rather than HL (12.5 %). 8 , 9 The chemotherapy is also used for treatment of lymphoma and it is different in HL and NHL. The anti-cancer agents including doxorubicin, bleomycin, vinblastine and dacarbazine are extensively applied in treatment of HL, while vincristine, cyclophosphamide and prednisone are employed for treatment of NHL.…”

Section: Introductionmentioning

confidence: 99%

Curcumin in treatment of hematological cancers: Promises and challenges

Entezari,

Tayari,

Paskeh

et al. 2024

Journal of Traditional and Complementary Medicine

View full text Add to dashboard Cite

Stem Cell as Vehicles of Antibody in Treatment of Lymphoma: a Novel and Potential Targeted Therapy

Cited by 5 publications

References 98 publications

Construction of tandem diabody (IL-6/CD20)-secreting human umbilical cord mesenchymal stem cells and its experimental treatment on diffuse large B cell lymphoma

Construction of tandem diabody (IL-6/CD20)-secreting human umbilical cord mesenchymal stem cells and its experimental treatment on diffuse large B cell lymphoma

Nanocarriers, Progenitor Cells, Combinational Approaches, and New Insights on the Retinal Therapy

Curcumin in treatment of hematological cancers: Promises and challenges

Contact Info

Product

Resources

About